untitled draft

untitled draft
London, UK
REPAIR Impact Fund Investment
4 million GBP (c. 32 million USD) Series A investment round
Company Website

Centauri is leveraging the Alphamer technology to introduce an innovative drug mechanism that recruits and directs pre-existing antibodies specifically to pathogens, engaging both innate and adaptive immunity to elicit an immune response that clears the infection. The continual emergence of AMR bacteria is resulting in increasingly difficult-to-treat infections, with an estimated 4.95 million global deaths associated with bacterial AMR in 20191. New modalities that can target these drug-resistant strains more effectively are urgently needed, and the Alphamer technology could help to broaden the anti-infective arsenal to reduce the global impact and improve patient outcomes.